Background: We conducted a phase I/II trial to assess the feasibility and activity of combination chemotherapy with etoposide, ifosfamide, cisplatin, and epinibicin in limited-stage (LS, stage I-IIIB) and extensive-stage (ES, stage IV) non-smallcell lung cancer (NSCLQ. End-points were treatment-related morbidity and mortality, response rate, duration of response, and survival.
Introduction
Despite the development of many new and active combinations of surgery, chemotherapy, and radiation, the survival of most patients with non-small-cell lung cancer has not significantly improved for decades [35, 37] . The median survival in limited and extensive stage NSCLC has largely remained at 12-16 and 3-6 months, and the 5-year survival at 5%-15% and 0%-3%, respectively [3, 6, 22, 25, 35, 37, 75] .
Even in patients with operable stage I and II NSCLC, curative therapy is attainable only for a minority [35] , while treatment of inoperable stage IIIB, and of stage IV NSCLC is uniformly palliative [1, 13-16, 53, 57, 71] . Stage IIIA assumes an intermediate position with the majority of cases behaving like stage IIIB, and a minority achieving survival comparable to stage II patients with neo-adjuvant multi-modality treatment protocols [2, 21, 30, 59, 60, 78] .
With benefits from surgery and radiotherapy optimized [17, 31, 49, 56] , improvements in chemotherapeutic efficacy are strongly needed [37] . However, despite a multitude of published trials, the value of cytostatic agents in the single-or multimodality treatment of nonsmall cell lung cancer remains controversial [25, 33, 47, 57, 63,64, 68-70, 73, 74] .
As in other solid tumors, chemotherapy dose intensification with or without hematopoietic growth-factor (HGF) support can induce moderate improvements of response rates, but without relevant survival benefits [20-22, 50, 52, 54] . As a result, the cost-effectiveness and toxicity of such treatments have been vigorously called into question [61, 68] .
High-dose chemotherapy (HDC) with autologous bone marrow or peripheral blood stem cell transplantation (ABMT/PBSCT) has been used in small number of patients with NSCLC [27, 77] . The results of these studies have been negative, with high rates of toxicity and mortality and no improvement in survival [63] .
Nevertheless, trials with escalated-dose combination chemotherapies indicate potential benefits for subsets of patients, such as stage IIIA patients rendered amenable to curative resection by intensified neo-adjuvant polychemotherapy [21, 54, 59, 60] . Therefore, HDC with PBSCT could benefit subgroups with NSCLC such as those in whom reponses to neo-adjuvant HDC open the path for resection, and those in whom minimal residual disease (MRD) after surgery or chemotherapy could be eradicated in an adjuvant setting.
In a phase I/II trial addressing these questions we chose VIP-E conventional-dose chemotherapy (CDC) as induction therapy in 107 patients with NSCLC. A subgroup of patients with favorable responses to VIP-E then underwent VIC-E HDC with PBSCT. VIP-E was selected for a number of reasons: (1) it includes four active agents in the treatment of NSCLC; (2) the treatment schedule is completed in 24 hours and repeated every 3 weeks, resulting in high dose-intensity as measured per mg/m 2 / week; (3) post-VIP-E neutropenia leads to rebound leucocytosis with G-CSF, which allows for harvest of PBPC in candidates for PBSCT. The efficacy and toxicity of VIP-E CDC and VIC-E HDC in the treatment of patients with NSCLC are presented. 
Patients and methods

Patient eligibility
Patients with histologically proven NSCLC were enrolled in the study between July 1989 and December 1995. For the conventional-dose arm of the study patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-3, a biologic age between 18 and 65 years, and no evidence of significant impairment of cardiac, pulmonary, renal, and hepatic function as evidenced by left ventricular ejection fraction > 50% by echocardiogram, forced expiratory volume in 1 second greater than 60%, creatinine clearance > 60 ml/ min, and liver function tests less than 2.5 times normal. All patients provided written informed consent in accordance with institutional and ethics comittee requirements.
Pretreatment characteristics
Seventy-two patients received VIP-E induction chemotherapy as first therapy of their malignancy, 35 patients were treated for relapse or progression after surgery or radiation. Twenty-five patients underwent 29 surgical procedures for primary NSCLC including 18 R-0 resections, 6 R-l resections, and 7 R-2 resections. Of 16 patients with prior R-0-resection 12 had inoperable relapse at time of VIP-E therapy.
Twelve patients received short courses of palliative prior radiation to symptomatic bony lesions. Five patients had received one or two courses of prior chemotherapy; 3 of these patients had had adjuvant chemotherapy after initial resection and presented with untreated relapse, 2 patients were referred after they failed one course of palliative CCNLV MTX chemotherapy. All patients are included in analysis of response and survival.
Patient characteristics
One-hundred-seven eligible patients entered the study, 32 had LS and 75 ES NSCLC. An overview of patient characteristics is given in Table 1 .
Pretreatment evaluation consisted of complete history and physical examination, complete blood count (CBQ, and serum chemistry including tumor markers. Staging procedures included bronchoscopy, chest X-ray, computerized tomography (CT) scans of chest, abdomen, and brain, and radio-isoptope bone scans; stage IIIA patients underwent mediastinoscopy. Stage classification according the International TNM Staging System (ISS) as adapted by Mountain [51] was used. Additionally, and in analogy to the Veterans Administration Lung Cancer Study Group staging system for SCLC, limited stage (LS) NSCLC was defined as intrathoracic disease including ipsilateral pleura! effusions with or without supraclavicular lymph node involvement;
Treatment plan conventional-dose VIP-E
Treatment consisted of etoposide (500 mg/m 2 ), ifosfamide (4000 mg/m 2 ), cisplatin (50 mg/m 2 ), and epirubicin (50 mg/m 2 ) given intravenously over 24 hours as described before [6] [7] [8] [9] [10] . Treatment sequence for VIP-E CDC was epirubicin (15-minute bolus), followed by etoposide (4-hour infusion in 2000 ml of normal saline (NS)), cisplatin (1-hour infusion in 250 ml of NS), and ifosfamide (18-hour infusion in 500 ml of NS).
Hydration with >4 liters fluid/day was maintained; standard uroprotection with MESNA at a dose of 4000 mg/m 2 /day was begun 0.5 hours before, and continued 24 hours after end of ifosfamide therapy. Harvesting of peripheral blood stem cells was performed on day +10 and +11 after the second course of VIP-E induction chemotherapy. Collected cells were frozen and stored in liquid nitrogen until clinical use.
Patients received a minimum of 2 cycles of CDC at 3-week intervals, and were treated for a maximum of 4 cycles if they maintained or achieved a PR or CR, or a response consistent with the definition of stable disease. Patients proceeding to HDC only received 2 cycles of V1P-E chemotherapy. Evaluation of response followed after 2 cycles and after completion of therapy. so far, died as a direct or indirect consequence of their disease and/or treatment of their disease.
Median follow-up in the CDC arm was 26 months (range, 8-53) in LS-NSCLC, and 37 months (13-64) in ES-NSCLC. Follow-up of HDC patients was 26 months (10-58) for LS, and 29 months (10-56) for ES. Median follow-up of all patients was 32 months (8-64).
Treatment plan high-dose VIC-E
HDC was given 3 weeks after the last VIP-E therapy at a cumulative dose of etoposide 1500 mg/m 2 , ifosfamide 12,000 mg/m 2 , carboplatin 750 mg/m 2 , and epirubicin 150 mg/m 2 (VIC-E) with transplantation of unpurged autologous peripheral stem cells 24 hours after completion of the last day of chemotherapy. Treatment sequence for VIC-E HDC was epinibicin (50 mg/m 2 as 15-minute bolus), followed by etoposide (500 mg/m 2 as a 4-hour infusion), and carboplatin (500 mg/m 2 ) with ifosfamide (4000 mg/m 2 ) running parallel as 18-hour-infusion. This treatment schedule was repeated on three consecutive days.
Surgical resection of primary tumor before or after chemotherapy was intended, and performed whenever feasible. Consolidating thoracic radiation therapy (TRT) was given to all patients in the high-dose arm, and to patients in PR or CR after conventional-dose VIP-E.
Patient eligibility for high-dose chemotherapy
LS and ES NSCLC patients with CR or PR after VIP-E conventionaldose chemotherapy (CDC) were eligible for HDC with the following qualifications: ECOG performance 0-2, biologic age < 60 years, and no major organ impairment after, or major toxicity with VTP-E CDC. Major organ impairment or or major toxicity with or after VIP-E CDC was defined as the occurrence of WHO grade III/1V toxicity in organs other than bone marrow (where such toxicity was expected); furthermore toxicity or adverse events leading to hospitalization after VIP-E CDC were included in this definition. Grade III/TVmucositis or nausea/ vomiting were counted as major toxicity only if they occurred after every cycle of CDC with similar or increased intensity.
Supportive care
Hematopoietic growth-factor (HGF) support with G-CSF was begun 24 hours after chemotherapy and continued until the first day with ANC > 1000/ul. Dose of G-CSF was 300 ug/day under, and 480 ug/day above 70 kg body weight.
Definition of toxicity
Side effects were assessed according to standard WHO-criteria of organ toxicity [76] .
Definition of response
Quality and duration of response were evaluated according to standard protocols [76] . Duration of response and survival were assessed according to the methods described by Kaplan and Meier [40] .
Follow-up
One hundred seven patients were included in the study between 1989 and 1995. Recruitment was stopped as of December 31,1995, and followup was censored as of July 1,1996. Time to relapse was measured as the last day of VIP-E treatment to the first objective documentation of recurrence or renewed progression. Survival was measured from end of last treatment to date of death. Death from any cause was included in survival evaluation. Patients alive were censored on the last day of contact. No patients were lost to follow-up. All patients who have died
Results
Patient eligibility for high-dose chemotherapy
Of 16 ES patients eligible by response (i.e., after attaining PR or CR; one ED patient with SD after CDC received neo-adjuvant HDC for planned resection of primary tumor and contralateral pulmonary metastasis), 3 were ineligible by these criteria, and 2 preferred CDC for concerns about toxicity. Of 23 LS patients eligible by response (i.e., after attaining PR or CR, or in an adjuvant setting), 5 were ineligible by these criteria, and 6 preferred CDC for concerns about toxicity. Ultimately, 13 of 16 (81%) and 12 of 23 (52%) eligible ES and LS patients underwent HDC and PBSCT, respectively.
The resulting differences between patients receiving only CDC and patients receiving CDC and subsequent HDC are shown in Table 2 . As expected, the latter group contained younger patients with better responses to CDC and a better performance score.
Hematologic toxicity -conventional-dose VIP-E
Toxicity in general, and hematologic toxicity in particular was more pronounced in patients with ES NSCLC or poor performance score. Despite two cases of prolonged granulocytopenia, chronic pancytopenia did not occurr. Details of hematologic toxicity are shown in Table 3 . Median duration of neutropenia < 1000 ANC/ul was 3 days. Transfusion requirements were moderate, with 8 patients requiring packed red blood cell (PRBQ, and 7 patients platelet transfusions (PT). One ES-patient with poor dentition who was non-compliant with G-CSF developed peptostreptococcus-bacteremia during neutropenia and required in-hospital i.v. antibiotic therapy.
Nonhematologic toxicity -conventional-dose VIP-E
Nonhematologic toxicities are shown in Table 3 . Infections lead to in-hospital treatment in 15% of patients.
Mortality -conventional-dose VIP-E
Mortality in the LS group was 1 of 32 (3%), while 6 of 75 (8%) ES NSCLC patients died of treatment-related complications. Five of six ES patients were male; age was 49, 54, 54, 60, 61, and 62; death occurred on day +5, +6, +6, +8, +9, and +14 after the first (n -5) or second (n -1) course of VIP-E, respectively. Cause of death was pancytopenic septic shock in 5 patients; organisms were found in 3 patients (E. coli, staphylococcus epidermidis and xanthomonas maltophilia). One 48-year-old male LS patient died in SD on day +14 after the second course of VIP-E of pulmonary hemorrhage possibly associated with aspergillosis; hematologic reconstitution was complete at time of death.
Hematologic toxicity -high-dose VIC-E
Median duration of ANC < 1000/JJ.I was days (range, 6-14) in both LS and ES SCLC; thrombopenia <20,000/ul lasted 8.5 days (6-15), and thrombopenia < 50,000/nl 15 days (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Median number of CD34+ cells transfused was 1.7 x 10 6 C34+ cells/kg/bw (range 1.04 to 5.6 x 10 ). Median transfusion requirements were 4.5 (1-10) PRBCs and 27 (6-99) PTs.
HDC-associated hematological toxicity is not shown in Table 4 since granulocytopenia and thrombopenia was grade IV in all patients; anemia was grade III in 21, and grade IV in 4 patients.
Nonhematologic toxicity -high-dose VIP-E
Details are shown in Table 4 .
Mortality -high-dose VIC-E
One 57-year-old female patient with ED NSCLC died after HDC and PBSCT on day +14; 2 months prior she had had R-2-resection of bilateral pulmonary adenocarcinomas. Death occurred in septic shock during pancytopenia and was likely due to bacterial pneumonia (no postmortem examination). 
Response to conventional-dose VIP-E
A total of 280 VIP-E cycles were given to 107 patients. All 107 patients received 2 to 4 (average 2.7) courses of VIP-E chemotherapy. Thirty-nine of one hundred two evaluable patients responded to VIP-E chemotherapy for an overall response rate of 38% (Table 5 ). Objective response rates (ORR) were 59% for LS, and 23% for ES. Including 4 patients treated in an adjuvant setting, ORR was 72% for LD SCLC. Duration of remission was short in ES patients (median 2.5 months). In LS response varied, with some patients achieving longer remissions (median 6 months). In 5 ES patients who died after the first cycle of VIP-E CDC response could not be assessed.
Response -high-dose VIC-E
Twenty-three of twenty-four evaluable patients responded to VIC-E HDC. All LS NSCLC patients improved (n = 5; > 50% reduction of residual tumor) or maintained (n -5) a prior partial response; one ES NSCLC patient converted from PR into CR, the remainder improved (n = 2) or maintained (n = 6) a prior PR (Table 6 ). Median Table 5 . Response to conventional-dose VIP-E. Table 6 . Response to high-dose VIC-E. for LS and ES NSCLC, respectively (Figures 1 and 2) . Predicted 2-year survival was 30% in LS (95% CI 9%-64%) and < 9% in ES SCLC (95% CI 0%-24%).
Treatment of relapse
A number of transient minor (25%-50% reduction) and partial (> 50% reduction of tumor mass) responses were observed after palliative monotherapy with 135 to 175 mg/m 2 paclitaxel in 11 of 16 patients treated for relapse. There was no CR and no curative treatment of relapse in any patient. Reponse of patients treated after CDC did not differ from the response of patients after HDC.
Survival-conventional-dose VIP-E
Eighty-two patients received VIP-E CDC without subsequent HDC. All were evaluable for survival. At time of last follow-up 71 (86%) had died, while 9 (11%) patients were alive with, and 2 (3%) free of disease. Of 20 LSpatients, 10 (50%) have died, 8 (40%) are alive with disease while 2 (10%) are alive in CR (Figure 1 ). Sixtyone of sixty-two (98%) ES-patients have died (Figure 2 ). Median duration of survival was 13 months for LS, and 5.5 months for ES NSCLC. Predicted 2-year survival is 26% in LS (95% CI 16%-44%) and < 2% (95% CI 0%-5%) in ES NSCLC. Adenocarcinomas more often had a longer clinical course, which is consistent with the observation that survival of platinum-refractory pulmonary adenocarcinomas can be superior to survival with other histologies [22] .
Survival -high-dose VIC-E
Twenty-five of one hundred seven (23%) patients in this study proceeded to HDC and PBSCT. Twelve patients with LS NSCLC underwent HDC; of these 6 have died, 2 are alive in relapse, and 4 in CR at 6+, 8+, 14+, and 46+ months. Median survival was 8 months for patients dying of relapse or toxicity, and 17+ months for patients achieving CR. Of 13 ES patients 12 (92%) have died, and 1 is alive in relapse. Median survival was 17 and 10 months 
Discussion
Chemotherapy with currently available agents does not have an independent curative role in the treatment of NSCLC. However, whether new chemotherapy protocols can improve the results of multi-modality treatment concepts in NSCLC, remains an open question [18, 59] . Our trial was designed to assess the activity of VIP-E CDC and VIC-E HDC as part of a multi-modality treatment of NSCLC.
The results obtained with CDC and HDC are not directly comparable because patients entering the highdose arm represent a selected minority of patients in this study. Treatment results of VIP-E CDC are therefore skewed to the worse, and results of VIC-E HDC artificially improved, since most patients with favourable characteristics proceeded to HDC and PBSCT. Taking this into account, the results of VIP-E CDC seem comparable to published standard-dose chemotherapy regimens in NSCLC [1, 3, 13, 15-18, 20, 21, 66] . Similarly, the results of VIC-E HDC with PBSCT are in accordance with known data [27, 77] .
The observation that achievement of PR or CR after CDC or HDC of inoperable NSCLC did not improve prognosis in our study indicates that -unlike the situation in SCLC -NSCLC is cured almost exclusively by surgery and that the value of chemotherapy in this disease entity consists mainly in its contribution to neo-adjuvant and adjuvant protocols [18, 63, 72, 79] . Indeed, with only two exceptions, objective reponses of over 6 months duration in our study were achieved only in surgically treated patients after either neo-adjuvant or adjuvant chemotherapy. The efficacy of VIP-E CDC and VIC-E HDC as neo-adjuvant or adjuvant therapy in stage IIIA NSCLC was, however, not assessed independently within this trial.
Given the poor operability of most LS-NSLC at initial diagnosis and the high rate of local and systemic relapse even in patients with resectable disease, using chemotherapy in either setting is nontheless reasonable and may even be insufficiently investigated [35] .
Palliative chemotherapy of NSCLC, on the other hand, has been frequently explored, and is discussed controversially in the literature [13-16, 53, 57] . It has been shown to alleviate tumor-related symptoms independently of measurable response rates and quantitative improvements in survival [63] . For palliative purposes VIP-E shares low response rates with similar protocols, while toxicity and mortality, especially in older patients with poor performance and in advanced NSCLC, are high [1] . Therefore, in the palliation of NSCLC, less toxic protocols are preferable.
These results add to the recent evidence questioning the value of escalated-dose chemotherapy in NSCLC [68] . A recent meta-analysis failed to find benefits from dose-intensified chemotherapy in NSCLC [37] . Moreover, conflicting data exist as to whether cisplatin, one of the most effective and most frequently dose-escalated agents in NSCLC, offers relevant improvements when used at higher dosages [68] .
With the relative success of surgery in stage I/II [46] , the good results of neo-adjuvant dose-intense CDC with or without TRT in operable stage IIIA [59] , the moderate survival with CDC and/or TRT in inoperable stage IIIA/ IIIB [31] , and the poor results of any treatment in stage IV [1] , there can be little interest in new forms of doseintense CDC or HDC that do not markedly improve response and survival in any of these settings.
Still, response and survival in both the CDC and the HDC subset of this study may stimulate further investigation in the neoadjuvant and adjuvant chemotherapy of selected younger (<55 years) patients with stage I, II and IIIA NSCLC. The potential benefit of such chemotherapy might increase with decreasing tumor size. Whether this approach will prove to be equivalent or superior to established combinations of chemo-and radiotherapy remains to be determined by future studies. Chemoradiation has been shown to yield survival benefits in select populations of NSCLC patients; 2-or 5-year survival, however, has not improved [30a, 61a] .
In summary, this study demonstrates the moderate efficacy and relatively high toxicity of VIP-E CDC in patients with NSCLC. Improvements in patient selection, supportive care, and perhaps utilization of new chemotherapy agents [12, 22, 32, 39, 43, 48, 75] , will be required before testing against established protocols can be justified. Similar qualifications apply to the role of HDC in NSCLC, whose role remains experimental in view our findings.
